c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins αvβ3 and αvβ5

Xiuhai Ren1*, Jingying Xu1, Jason P. Cooper2, Min H. Kang2, Anat Erdreich-Epstein1,3*

1 Division of Hematology-Oncology, Department of Pediatrics, Keck School of Medicine, University of Southern California and the Saban Research Institute of Children’s Hospital Los Angeles, Los Angeles, California, United States of America, 2 School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America, 3 Department of Pathology, Keck School of Medicine, University of Southern California and the Saban Research Institute of Children’s Hospital Los Angeles, Los Angeles, California, United States of America

Abstract

Inhibition of integrins αvβ3/αvβ5 by the cyclic function-blocking peptide, RGDfV (Arg-Gly-Asp-Phe-Val) can induce apoptosis in both normal cells and tumor cells. We show that RGDfV induced apoptosis in ECV-304 carcinoma cells, increased activity and mRNA expression of acid sphingomyelinase (ASM), and increased ceramides C16:0, C18:0, C24:0 and C24:1 while decreasing the corresponding sphingomyelins. siRNA to ASM decreased RGDfV-induced apoptosis as measured by TUNEL, PARP cleavage, mitochondrial depolarization, and caspase-3 and caspase-8 activities, as well as by annexinV in a 3D collagen model. These findings indicate a causal role for ASM in RGDfV-induced apoptosis in ECV-304. We have shown that c-Abl, a non-receptor tyrosine kinase, also mediates RGDfV-induced apoptosis. However, c-Abl, has not been previously linked to ASM in any system. Here we show that STI-571 (imatinib, inhibitor of c-Abl) inhibited RGDfV-induced ASM activity. Furthermore, STI-571 and c-Abl-siRNA both inhibited RGDfV-induced increase in ASM mRNA, but ASM-siRNA did not affect c-Abl phosphorylation or expression, supporting that c-Abl regulates the RGDfV-induced increase in ASM expression. These studies implicate ASM as a mediator of apoptosis induced by inhibition of integrins αvβ3/αvβ5, and for the first time place c-Abl as an upstream regulator of ASM expression and activity.

Introduction

Integrins, heterodimeric cell-surface receptors, are central regulators of cell functions such as proliferation, differentiation, growth factor secretion and protection from apoptosis [1,2,3]. Integrins αvβ3 and αvβ5 are expressed on a variety of cell types including cancer cells and endothelial cells [3,4,5,6]. Inhibition of integrins αvβ3 and αvβ5 can induce cell death and affect tumor growth [7,8,9,10]. Integrins αvβ3 and αvβ5 bind to arginine-glycine-aspartic acid (RGD)-containing matrix proteins such as vitronectin. Integrin αvβ3/αvβ5 signaling can be blocked by soluble function-blocking RGD peptides such as the cyclic RGDfV (Arg-Gly-Asp-Phe-Val) peptide, resulting in apoptosis [8,9,11]. In vivo RGDfV inhibits growth of cell line-derived tumors such as glioblastoma, medulloblastoma, and breast cancer in mice [3,12]. Moreover, the clinical version of RGDfV, Cilengitide, is in clinical trials [12,13,14,15], underscoring the need to fully understand the molecular mechanism(s) that are affected by RGDfV.

Ceramide, an intracellular sphingolipid second messenger, can be increased by pro-apoptotic stimuli such as UV, ionizing irradiation and lipopolysaccharide [10,16,17,18,19,20,21], and is thought to have pro-apoptotic function. Two central pathways for generation of ceramide in apoptosis are de novo synthesis starting with condensation of palmitoyl-CoA to serine, catalyzed by serine palmitoyltransferase, and hydrolysis of sphingomyelin by sphingomyelinases [17,18,22,23]. Acid sphingomyelinase (ASM) can mediate apoptosis induced by stimuli such as irradiation, lipopolysaccharide (LPS), and others [24,25,26]. Using thin layer chromatography and pharmacological inhibitors, we have shown that inhibition of integrins αvβ3/αvβ5 by RGDfV increases incorporation of [3H]palmitic acid into ceramide species and is associated with apoptosis [11,27]. In that setting, the nonspecific ASM inhibitors desipramine, imipramine (tricyclic antidepressants) and SR33557 (a calcium channel blocker) decreased apoptosis induced by RGDfV, suggesting that ASM may be the mediator of the increase in ceramide, and that this sphingolipid pathway may be required for RGDfV-induced apoptosis [11]. However, these inhibitors have functions other than inhibition of ASM, and therefore, a role for ASM in RGDfV-induced apoptosis remained inconclusive.

c-Abl is a non-receptor tyrosine kinase mostly known for its proliferative and oncogenic potential. c-Abl is clinically important...
as the constitutively-active kinase in the oncogenic fusion protein BCR-ABL1 in chronic myelogenous leukemia and in some acute lymphoblastic leukemias [28,29]. Interestingly, c-Abl can also mediate apoptosis induced by stimuli such as DNA damage-inducing agents and disruption of cell shape, and we recently showed that it was required for apoptosis induced by inhibition of integrins αβ3/αβ5 by RGDIV [30,31,32,33]. However, it is completely unknown whether the molecular mechanism of c-Abl and ASM in RGDIV-induced apoptosis are interconnected.

In the work presented here we addressed two questions: 1) does ASM mediate RGDIV-induced apoptosis, and 2) do ASM and c-Abl function in separate pathways or in the same apoptotic signaling pathway initiated by RGDIV, and if the latter, what is their molecular ordering. Our data now show that inhibition of integrins αβ3/αβ5 by RGDIV, which induced ECV-304 apoptosis, increased ASM activity and mRNA expression, and that this ASM increase was required for apoptosis. Further, while c-Abl inhibition and knockdown blocked the RGDIV-induced increase in ASM activity and mRNA expression, ASM knockdown had no effect on RGDIV-induced c-Abl phosphorylation. These data indicate that ASM mediates RGDIV-induced apoptosis and that c-Abl acts upstream of ASM in this apoptotic pathway. This is the first report linking the pro-apoptotic role of c-Abl to ASM and the first to identify c-Abl as a regulator of ASM.

Materials and Methods

Apoptosis Assay

Apoptosis was evaluated by flow cytometry in cells (combined adherent and non-adherent) using the Apo-Direct kit (Becton Dickinson) detecting terminal deoxynucleotidyltransferase (TdT) activity as incorporation of FITC-dUTP (fluorescein isothiocyanate-deoxyuridine triphosphate) compared with propidium iodide (PI) incorporation according to the manufacturer’s instructions. Apoptosis in cells grown in three-dimensional (3D) collagen type I was evaluated using the AnnexinV-FITC fluorescence microscopy kit (BD Biosciences) according to manufacturer’s instructions as described [33,34]. Fluorescent images were acquired on an Olympus CKX41 microscope and photographed using PictureFrame 2.1 software (Optronics; original magnification x400) [33].

ASM Activity Assay

ASM activity was determined using the ASM Assay Kit (#K-3200, Echelon Biosciences, Salt Lake City; UT) according to manufacturer’s instructions, using conditions that yielded readings in the linear range of the assay. Cell lysates (prepared by three freeze/thaw cycles in presence of 1 mM PMSF; 1.2 μg protein/sample) were incubated overnight at 37°C with 50 μl substrate. Fluorescence intensity was read at 360 nm excitation/460 nm emission using a Synergy HT microplate reader (Bio-TEK Instruments, Inc., Winooki, VT). ASM activity was calculated using the standard curve of ASM enzyme activity supplied with the kit and was normalized to protein content (nmol/h/mg sample protein).

Caspase Activation Assay

Caspase activities were measured using the ApoTarget Caspase-3/CPP32 and Caspase-8/FLICE Colorimetric Protease Assays (BioSource, CA) and were determined in 200 μg lysate protein suspended in 50 μl extraction buffer according to manufacturer’s instructions and as described [33]. Absorbance at 400/405 nm was determined after 16 hrs incubation (37°C) with substrate.

Cell Culture

The ECV-304 bladder carcinoma cell line (ATCC CRL-1998, Manassas, VA; expresses integrin αβ3 [35,36] and data not shown) was maintained in RPMI-1640 with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 20 mM HEPES. For experiments with RGDIV, cells were seeded in serum-free medium on vitronectin-coated plates (2 μg/ml) that were blocked with 1% heat-denatured fatty-acid-free bovine serum albumin (HD-BSA) as described [11,33,37]. RGDIV (5 μg/ml) or vehicle were added when cells were attached and spread (2–16 hrs after cells were transferred to Petri dishes). Cells were incubated with RGDIV or vehicle for 24 hrs for western blotting and caspase assays and 48 hrs for flow cytometry assays, or as indicated.

LC/MS/MS Analysis of Intracellular Sphingolipids

Sphingolipids were determined in duplicate by ESI/MS/MS performed on a ABI 4000Qtrap triple quadrupole mass spectrometer, operating in a multiple reaction monitoring positive ionization mode as described, with moderate modifications [38]. Briefly, 5×105 cells/sample were trypsinized, washed with ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing 130 mM NaCl, 5 mM EDTA, and 5 mM EGTA, and snap-frozen until use. Internal sphingolipid standards consisting of 50 μl mixture containing 1 pM C17-phosphoglycerine (Spb), C17-dehydrophospho- sine (dhSpb), C17-phosphoglycerine-1-phosphate (SP1), and C17-Ceramide (Avanti Polar Lipids, Inc, Alabaster, AL) were added to cell pellets before lipid extraction with 4 ml ethyl acetate/isopropyl alcohol/water (60:30:10% v/v) solvent system. After centrifugation the organic layer was transferred to glass tubes and evaporated under a stream of air at 40°C. Samples and standards were reconstituted with 4 ml MeOH, 1 ml of the lipid extract was used for determination of phospholipid (P) and sphingomyelins as described (30), and the remaining extract was used for quantitation of ceramides by ESI/MS/MS. For ESI/MS/MS, the dried lipid extract was dissolved in HPLC mobile phase (0.5 ml, 1 mM ammonium formate in methanol containing 0.1% v/v formic acid). Lipid samples (10 μl) were injected onto the Agilent 1200 HPLC combined with the ABI 4000Qtrap MS/MS system and gradient-eluted from a BDS Hypersil C8, 150×3.2 mm, 3-μm particle size column, with 1 mM methanolic ammonium formate with 0.1% (v/v) formic acid, 2 mM aqueous ammonium formate with 0.1% formic acid (v/v) mobile phase system. Peaks corresponding to the target sphingolipid analytes and internal standards were collected and processed using the Analyst software system. Quantitative analysis was based on calibration curves generated by spiking an artificial matrix with known amounts of target analyte synthetic standards and an equal amount of internal sphingolipid standards. Target analyte/internal sphingolipid standards peak area ratios were plotted against analyte concentrations, which were normalized to their respective internal sphingolipid standards and compared with the calibration curves, using a linear regression model. Levels of sphingolipids in different cell samples were normalized to P.
RNA Interference

Two specific siRNAs for ASM, HS_SMPD1_1_HP (ASM1) and HS_SMPD1_2_HP (ASM2) and a scrambled control sequence (AllStars negative control siRNA) were from Qiagen (Valencia, CA). c-Abl siRNA (5'-GAAGGAGGAGGUGAGCAU3') was from Ambion (Austin, TX). ECV-304 (2 x 10^5 cells) seeded in 6-well plates and allowed to grow overnight were transfected with 100 pM siRNA or mock-transfected for 5 hrs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For RGDfV experiments transfection was done on vitronectin-coated 5 hrs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For both reactions denaturation was at 95°C for 45 sec, annealing at 56°C for 45 sec, and extension at 72°C for 1 min. ASM was amplified for 27 cycles and GPDH for 23 cycles, and products were separated on a 1.5% agarose gel.

Reagents

Ceramides, dihydroceramides, sphingomyelins, sphingoid bases, and their phosphates were from Avanti Polar Lipids, Inc (Alabaster, AL). RGDfV (NSC#70544; Cilengitide) was from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute. STI-571 (imatinib mesylate) was a kind gift from Novartis. Vitronectin was generated as described [11,33,37]. Collagen type I used for 3D culture was from BD Biosciences. All other reagents were from Sigma-Aldrich (St. Louis, MO) unless stated otherwise.

SDS-PAGE and Western Blotting

Cell pellets re-suspended in SDS sample buffer were sonicated, boiled 5 min and resolved on a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gel (10%) as described [11]. Primary antibodies for western blots were: anti-c-Abl 8E9, mouse monoclonal (1:1000) from BD Biosciences; anti-c-Abl K-12, rabbit polyclonal (1:1,000); anti-phospho-c-Abl (Y412), rabbit polyclonal (1:1,000) from Abcam; anti-ERK1 K-25, rabbit polyclonal (1:1,000); anti-GAPDH, mouse monoclonal (1:20,000) from Santa Cruz Biotechnology (Santa Cruz, CA); anti-β-actin, mouse monoclonal (1:20,000) from Sigma (St. Louis, MO). Detection was by ECL (Amersham Biosciences, Piscataway, NJ) and densitometry was analyzed by ImageJ (National Institutes of Health).

Statistical Analysis

Statistical analyses were performed using GraphPad Prism 5.0c for Macintosh (GraphPad Software, San Diego, CA). All experiments were repeated at least three times unless indicated otherwise. Data are expressed as mean ± standard error of the mean (SEM). P-values were calculated by unpaired t-test unless indicated otherwise, and are detailed in the graphs, legends, or tables. Significance level was set at p<0.05.

Results

Inhibition of αβ3/αβ5 Integrins by RGDfV Inhibits Apoptosis and Upregulates ASM mRNA and ASM Activity

ECV-304 cells express integrin αβ3 and αβ5 [35,36]. Inhibition of integrins αβ3 and αβ5 by RGDfV resulted in apoptosis of ECV-304 cells seeded on vitronectin (Fig. 1A; also supported by PARP cleavage, caspase-3 and caspase-8 activation, mitochondrial depolarization and AnnexinV staining shown in the non-silencing siRNA controls of the third and fourth figures). The response of ECV-304 to RGDfV was associated with a mean 2.5 fold increase in ASM activity that was detected after four hours or longer of exposure to RGDfV (baseline: 22.1 ± 1.4 vs. at 4h: 51.5 ± 5.3 ng/h/mg protein, p<0.001), but not in the first 5–60 min (Fig. 1B; also supported by the first two columns in panel B of the fifth figure). In view of this relatively late time course, we asked whether the increased activity could be due to change in ASM expression. Indeed, using real time quantitative RT-PCR (qRT-PCR) we consistently observed increase in ASM mRNA in cells incubated with RGDfV (mean 1.70 ± 0.11 fold increase after 24 hrs incubation in 16 separate experiments, each performed in 1–4 replicates; p<0.001), which persisted at least up to 96 hrs incubation (Fig. 1C and data not shown). Consistent with increase in ASM activity and ASM mRNA, mass spectrometry showed that exposure of ECV-304 cells to RGDfV significantly increased level of four ceramide species (C16, C18, C22, and C24 ceramide) and decreased sphingomyelins (SM) C14:1-SM, C16:0-SM, C18:0-SM, and C22:1-SM by 18% –35% (Fig. 1D–E and Table 1 NC vs. RGDfV). Thus, inhibition of integrins αβ3/αβ5 by RGDfV, that leads to ECV-304 apoptosis, is associated with increased ASM mRNA, increased ASM activity, enhanced hydrolysis of specific sphingomyelins, and increase in ceramides.

ASM Knockdown Attenuates RGDfV-induced Apoptosis

Acid sphingomyelase mediates apoptosis in response to a number of stimuli [24,25,26], but it has not been definitively shown yet if it mediates RGDfV-induced apoptosis. We therefore knocked down ASM by siRNA and examined effect on RGDfV-
induced apoptosis compared to non-silencing control siRNA. The two siRNAs to ASM: #1 (ASM1) and #2 (ASM2), deceased ASM mRNA by 80–90% at 48–72 hrs compared to non-silencing control or ERK siRNA (Fig. 2A and data not shown). Functionally, the decrease in ASM mRNA induced by siRNAs ASM1 and ASM2 (Fig. 2A) was paralleled by decrease in the

**Figure 1.** RGDfV increases ASM mRNA, ASM activity and ceramide levels and decreases sphingomyelins. A) Apoptosis (Apo-Direct kit) in ECV-304 cells treated with vehicle or RGDfV (5 μg/ml; 48 hrs). Left panel: representative flow cytometry plots showing percentage of apoptotic cells (FITC-dUTP positive cells in the two upper quadrants; dark blue dots). Color dots in the lower quadrants represent position in the cell cycle of the non-apoptotic cells based on DNA content (propidium iodide). Light blue is sub G0, green is G1, orange is S-phase and red is G2/M. Right panel: mean ± SEM apoptotic (dark blue) cells of 24 independent experiments. B) ASM activity (Echelon Biosciences kit) in extracts from ECV-304 treated with vehicle or RGDfV (5 μg/ml). Shown are mean ± SEM of three independent experiments. C) Real time quantitative RT-PCR for ASM from ECV-304 cells treated with vehicle or RGDfV (24 hrs). Shown are mean ± SEM ASM mRNA normalized to GAPDH, depicted as fold-increase compared to baseline from 16 independent experiments performed in 1–4 replicates each. D–E) Change in ceramide (D) and sphingomyelin (E) content in extracts from ECV-304 cells incubated with vehicle or RGDfV (5 μg/ml; 24 hrs) and analyzed by mass spectrometry. Bars represent mean ± SEM fold change from control in one of two experiments with similar results, each of which was performed in 3 biological triplicates and analyzed in duplicates.

doi:10.1371/journal.pone.0042291.g001
RGDfV-induced increase in AnnexinV-positive cells was abolished in cells with siRNA directed against ASM, demonstrating activity of ASM (Fig. 2B). Last, the ceramide increase and sphingomyelin decrease induced by RGDfV were mostly abolished in cells with siRNA directed against ASM, demonstrating that the RGDfV-induced changes in most of these sphingolipids were induced by ASM (Fig. 2C–D and Table 1).

To determine if ASM mediated the RGDfV-induced apoptosis we next tested if ASM siRNA would block RGDfV-induced apoptosis in ECV-304 cells. Downregulation of ASM by siRNAs ASM1 and ASM2 decreased TUNEL stain induced by RGDfV compared to non-specific siRNA negative controls (Fig. 3A–B). Further, siRNA to ASM mitigated the cleavage of PARP induced by RGDfV (Fig. 3C–D). Last, in cells cultured in a 3D-collagen matrix, simulating more physiological conditions compared to two dimensional culture plates, inhibition of intrins by RGDfV in control cells (treated with nonspecific non-silencing siRNA) increased FITC-AnnexinV-positive cells more than four-fold (p < 0.001). However, if ASM was knocked down by siRNAs, the RGDfV-induced increase in AnnexinV-positive cells was abolished (p = 0.11 for siRNA ASM1 and p = 0.13 for siRNA ASM2 using vehicle vs. RGDfV-treated cells; Fig. 3E–F). Complementing this, the increase in AnnexinV-positive cells induced by RGDfV in ASM-siRNA cells was blocked compared to control siRNA cells (p < 0.001; Fig. 3F).

We next tested if ASM-siRNA could alter RGDfV-induced caspase cleavage, caspase activity and mitochondrial membrane depolarization in ECV-304 compared with non-silencing control siRNA (Fig. 4). RGDfV increased activity of caspase 3 and caspase 8 in non-silencing siRNA cells to 310±35% and 180±30% of control, respectively (Fig. 4A–B). However, in siRNAs ASM1- and ASM2-treated samples, the RGDfV-induced activation of both caspase 3 and caspase 8 (Fig. 4A–B) was significantly diminished, demonstrating that ASM functions upstream of caspase 3 and caspase 8 and is required for their activation during RGDfV-induced apoptosis.

RGDfV-induced apoptosis was also associated with mitochondrial depolarization as measured by the JC-1 mitochondrial probe (Fig. 4C–D). Downregulation of ASM using ASM1 or ASM2 siRNAs, but not non-specific non-silencing siRNA, diminished this activity of ASM (Fig. 2B). Last, the ceramide increase and sphingomyelin decrease induced by RGDfV were mostly abolished in cells with siRNA directed against ASM, demonstrating that the RGDfV-induced changes in most of these sphingolipids were induced by ASM (Fig. 2C–D and Table 1).

Table 1. RGDfV increases ceramides and decreases sphingomyelins, and these changes are abrogated following ASM knockdown.

| Ceramides (pmol/nmol Pi) | C14-CER | C16-CER | C18:0-CER | C18:1-CER | C20:0-CER | C22:0-CER | C24:0-CER | C24:1-CER |
|------------------------|---------|---------|-----------|-----------|-----------|-----------|-----------|-----------|
| NC                     | 0.44±0.08 | 3.17±0.13 | 0.10±0.01 | 0.04±0.01 | 0.15±0.03 | 1.85±0.21 | 3.35±0.35 | 7.83±0.59 |
| NC+RGDfV              | 0.47±0.07 | 4.76±0.29 | 0.14±0.01 | 0.05±0.01 | 0.13±0.01 | 1.94±0.14 | 4.26±0.17 | 10.14±1.09 |
| p value               | NS      | 0.008   | 0.042     | NS        | NS        | NS        | 0.039     | 0.016     |
| ASM1                  | 0.43±0.05 | 3.09±0.51 | 0.1±0.01  | 0.06±0.01 | 0.15±0.02 | 1.85±0.19 | 2.48±0.17 | 6.93±0.57 |
| ASM1+RGDfV            | 0.36±0.02 | 3.30±0.29 | 0.1±0.01  | 0.06±0.01 | 0.11±0.01 | 1.94±0.23 | 3.4±0.16  | 7.59±0.24 |
| p value               | NS      | NS      | NS        | NS        | NS        | NS        | 0.021     | NS        |
| ASM2                  | 0.36±0.01 | 2.60±0.21 | 0.09±0.01 | 0.06±0.01 | 0.14±0.01 | 1.77±0.14 | 3.16±0.37 | 7.07±0.31 |
| ASM2+RGDfV            | 0.40±0.03 | 4.13±0.55 | 0.11±0.01 | 0.07±0.02 | 0.12±0.03 | 1.92±0.29 | 3.59±0.50 | 8.61±1.06 |
| p value               | NS      | 0.061   | NS        | NS        | NS        | NS        | NS        | NS        |

| Sphingomyelins (pmol/nmol Pi) | C14-SM | C16-SM | C18:0-SM | C18:1-SM | C20:0-SM | C22:0-SM | C24:0-SM | C24:1-SM |
|-----------------------------|--------|--------|----------|----------|----------|----------|----------|----------|
| NC                          | 1.36±0.00 | 46.02±2.79 | 1.70±0.14 | 43.83±1.57 | 4.12±0.39 | 21.51±1.60 | 0.6±0.06 | 65.11±2.62 | 11.47±0.69 |
| NC+RGDfV                   | 0.94±0.02 | 38.04±0.46 | 1.36±0.09 | 37.71±1.16 | 3.07±0.24 | 17.19±0.39 | 0.41±0.05 | 51.27±1.35 | 8.61±0.42 |
| p value                    | 0.001  | 0.047  | 0.035     | NS        | NS        | NS        | 0.018     | 0.024     |
| ASM1                       | 1.31±0.08 | 50.47±1.17 | 2.28±0.22 | 59.5±3.06 | 5.04±0.53 | 27.67±1.03 | 0.63±0.10 | 73.40±2.45 | 12.29±0.87 |
| ASM1+RGDfV                 | 1.23±0.20 | 51.04±2.61 | 2.25±0.20 | 63.94±6.96 | 4.81±0.34 | 27.02±2.17 | 0.57±0.08 | 73.59±3.99 | 11.55±0.99 |
| p value                    | NS      | NS      | NS        | NS        | NS        | NS        | NS        | NS        |
| ASM2                       | 1.55±0.06 | 57.51±10.26 | 3.63±0.55 | 89.99±9.11 | 7.58±1.28 | 35.79±6.49 | 0.98±0.19 | 82.08±15.31 | 15.09±2.76 |
| ASM2+RGDfV                 | 1.23±0.12 | 56.39±14.60 | 3.73±1.07 | 99.79±27.60 | 7.46±1.88 | 34.78±8.66 | 0.90±0.29 | 79.38±13.78 | 14.67±4.20 |
| p value                    | NS      | NS      | NS        | NS        | NS        | NS        | NS        | NS        |

Lysates of cells treated with siRNA and RGDfV as in Figs. 2C–D as were analyzed by mass spectrometry as detailed in Methods. Sphingolipid nomenclature: Ceramides are 1,3-hydroxy-2-amino alkanes (sphinganine) or alkenes (sphingosine) with fatty acid alkyl chains of C14 to C24 linked to the amino group of the sphingosine or sphinganine. A double bond in fatty acid alkyl chains is indicated as number “1” in the name. For example, C14-CER is sphingosine + C14 fatty acid without a double bond, and C18:1-CER is sphingosine + C18 fatty acid with a double bond. Sphingomyelins (SM) have sphingosine with the 1-hydroxyl group modified to phosphocholine as a core structural moiety, and the numbers for SM are the number of carbons of fatty acid chain. The levels of C20:1-CER, C22:1-CER and C20:1-SM were below the level of detection and were thus not included in the table. Shown are means of three independent experiments ± SEM. NS: not statistically significant. doi:10.1371/journal.pone.0042291.t001
RGDfV-induced mitochondrial membrane depolarization by up to 50–60% (Fig. 4C–D). These results place ASM upstream of mitochondrial membrane depolarization in RGDfV-induced apoptosis.

Taken together, these data demonstrate that increase in ASM mediates the apoptosis induced by RGDfV, and that ASM functions upstream of caspase 8, caspase 3 and mitochondrial depolarization.
Inhibition of c-Abl Attenuates RGDfV-induced Increase in ASM mRNA and ASM Activity

In Figs. 1, 2, 3, 4 we showed that increased ASM is required for apoptosis induced by RGDfV in ECV-304 cells. We recently showed that RGDfV induces phosphorylation of c-Abl on tyrosines Y412 and Y245 and that c-Abl is required for RGDfV-induced apoptosis [33]. This raised the question of whether c-Abl and ASM signaling were functionally-related in RGDfV-induced apoptosis or were independent of each other.

We first tested the effects of the c-Abl inhibitor STI-571 (imatinib) on ASM (Fig. 5A–B). We found that STI-571 (5µg/ml) completely inhibited RGDfV-induced increase in ASM mRNA expression (Fig. 5A, p < 0.001) and the associated increase in ASM activity (Fig. 5B, p = 0.004), suggesting that ASM is regulated by c-Abl. c-Abl siRNA also mitigated the RGDfV-induced increase in ASM mRNA (Fig. 5C), further supporting the idea that c-Abl and ASM signaling are functionally related.
that c-Abl participates in regulation of ASM. Efficacy of c-Abl siRNA knockdown is shown in Fig. 5D). Consistent with these data, inhibition of c-Abl by STI-571 abrogated the increase in ceramides C16 and C18 that were observed in presence of RGDfV in cells with unhindered c-Abl (Fig. 5E). Similar experiments using siRNA showed that whereas RGDfV tended to increase ceramides C16 and C18 in cells with non-silencing control siRNA (p-values approaching significance), in cells with knocked down c-Abl there was no difference in ceramides C16 and C18 in presence or absence of RGDfV (Fig. 5E). siRNAs to ASM (ASM1, ASM2) however, were not able to block RGDfV-induced phosphorylation of c-Abl at Y412, nor did they change c-Abl protein expression (Fig. 5F–G). This molecular ordering of c-Abl and ASM places c-Abl as an upstream regulator of ASM in this apoptosis (Fig. 6).

Discussion
Our study demonstrated a causal role for ASM in apoptosis induced by integrin αvβ3/αvβ5 inhibition by RGDfV in ECV-304 carcinoma cells and showed that the increase in ASM was regulated by c-Abl.

**RGDfV Increases Acid Sphingomyelinase Expression**
Our findings add integrin αvβ3/αvβ5 inhibition to other stimuli in which ASM mediates apoptosis [39] and for the first time provide quantitation of changes in ceramide and sphingomyelin following exposure to RGDfV. These findings are consistent with those of Chudakov et al, who showed that ASM mediates apoptosis induced by knockdown of αv-integrins in oligodendrocytes [10]. Of note, pharmacological inhibition of integrins αvβ3/αvβ5 (i.e., RGDfV), which in vivo inhibits angiogenesis and tumor growth, may be biologically different from genetic knockdown of αvβ3/αvβ5, which can result in enhanced...
Figure 5. Inhibition of c-Abl abrogates the RGDfV-induced increase in ASM mRNA and ASM activity. 

A–B) ECV-304 cells were treated with STI-571 (c-Abl inhibitor; 10 µM) or vehicle starting 2 hrs before adding RGDfV (5 µg/ml) or vehicle for additional 24 hrs. (A) ASM mRNA (real time qRT-PCR; mean±SEM of 4 independent experiments performed in 2 replicates), (B) ASM activity (Echelon Biosciences kit; mean±SEM of 2 independent experiments performed in 4 replicates). C–D) ASM mRNA (real time qRT-PCR relative to GAPDH) of ECV-304 transfected with non-specific non-silencing negative control siRNA (NC) or c-Abl siRNA (48 hrs) and incubated with RGDfV (5 µg/ml) or vehicle for 24 hrs. Shown are mean±SEM, n = 4. Representative efficacy of c-Abl siRNA knockdown (western blot) is shown in Panel D. E) Change in ceramide content in extracts from cells incubated with STI-571 or siRNA-c-Abl and their controls with/without RGDfV as in panels A–D was analyzed by mass spectrometry.
angiogenesis [40]. Thus, it is interesting that both are mediated by ASM.

Our finding, that the increase in ASM activity was only detected after hours of RGDfV treatment (Figs. 1B, 2C, 5B) suggests that the increased ASM activity may be at least in part due to the increase in ASM mRNA. This time frame is consistent with results reported by Chudakova et al, who demonstrated that siRNA-mediated knockdown of integrin αvβ3 in oligodendrocytes was associated with late (≥48 hrs) sphingomyelin hydrolysis and ceramide accumulation [10]. A second possible explanation may be that the gradual effect of the stimulus (RGDfV, or siRNA to αv-integrin [10]) may contribute to this relatively late timeline, although the effect of RGDfV on cell morphology and integrin inhibition occurred within several hours.

Our results show a 50% increase in ASM mRNA following RGDfV (Fig. 1C), but >2-fold increase in ASM activity (Fig. 1B). This may suggest that in addition to the increased ASM mRNA, there may be further regulation of ASM activity by post-translational modification(s), such as the PMA-induced PKCδ-mediated serine 508 phosphorylation of ASM described by Zeidan and Hannun [41].

Our result place caspase 8 downstream of ASM. This is reminiscent of the mechanism of CD95-induced apoptosis, where initially caspase 8 is mildly activated (~1% of maximal activity), causing activation and translocation of ASM, and then achieves maximal activation following ASM-induced ceramide generation [42].

**Molecular Ordering of c-Abl and ASM in RGDfV-induced Apoptosis**

Our data place c-Abl upstream of ASM in RGDfV-induced ECV-304 apoptosis. To date, there have been no other reports implicating both c-Abl and ASM in the same pathway in apoptosis. The only other studies linking sphingolipid metabolism to Abl were performed in the context of the oncogenic forms of Abl (BCR-ABL1 and v-Abl), where Abl was protective rather than pro-apoptotic. For example, both BCR-ABL1 and v-Abl protected leukemia cells from ASM-mediated Fas-induced apoptosis [43]. A possible explanation for the difference may be that oncogenic forms of Abl do not undergo the nuclear translocation required for manifestation of the growth-inhibitory and/or apoptosis-mediating effects of c-Abl [30,33,44]. Therefore, our findings are the first to demonstrate a functional link between c-Abl and ASM and to provide their molecular ordering in apoptosis.

A role for c-Abl in regulation of ASM in apoptosis is supported by reports of several investigators using different cell types, which implicate either c-Abl or ASM in cisplatin-induced apoptosis. Zeidan et al demonstrated cisplatin-induced transient activation of ASM in MCF-7 cells [45] and Rebillard et al showed that ASM-deficient mice were protected from cisplatin-induced gastrointestinal damage [46]. Gonfloni et al then showed that cisplatin-induced apoptosis was mediated by c-Abl, by inducing accumulation of p63 in mouse oocytes [47]. It would be interesting to examine if c-Abl also regulates ASM in cisplatin-induced apoptosis or other apoptotic stimuli that involve c-Abl and/or ASM.

As noted, c-Abl mediates cisplatin-induced mouse oocyte apoptosis by causing accumulation of p63, a p33-family member [47]. P53 can mediate the modulation of DNA damage-induced apoptosis by cell adhesion [48]. c-Abl, a modulator of DNA damage-induced apoptosis, can also mediate this adhesion-dependent modulation of apoptosis, but in a p33-independent manner [49]. c-Abl also regulates p73, another p33 family member [47].
member, in the apoptotic response to cisplatin-induced DNA damage, in which ASM plays a role [45,50]. In endothelial cells, p53 is activated following inhibition of integrins αvβ3/αvβ5 by RGDIV [51], suggesting possible interactions between p53 and c-Abl, and/or ASM. Examination of change in p53, p63, or p73 protein levels following manipulation of c-Abl (siRNA or STI-571) in RGDIV-induced apoptosis will be interesting, but will require use of cells other than ECV-304, which have truncated p53 due to an in-frame deletion of tyrosine 126 [52].

c-Abl, typically evoked for its proliferative effects [28,29,53] and as mediator of DNA damage-induced apoptosis [30,31], is also an important regulator and target of cytoskeletal dynamics [54,55,56]. A number of studies have also linked ASM to cytoskeletal control: Zeidan et al. elegantly demonstrated that cisplatin-induced cytoskeletal remodeling in MCF-7 breast adenocarcinoma cells was mediated by transient activation of ASM, which in turn caused dephosphorylation (inhibition) of another actin-binding protein, ezrin [at threonine 567] [45]. The functional output in that study was cytoskeletal remodeling and motility, both of which occur at earlier time points than apoptosis [45]. Rebillard et al. recently showed that cisplatin-induced apoptosis required F-actin cytoskeletal reorganization mediated by Fas, and that ezrin was also required for that apoptosis [57]. Interestingly, integrin αvβ3 binding to vitronectin causes phosphorylation of ezrin [58]. It remains to be seen whether ezrin will also emerge as an effector in the signaling cascade initiated by integrin αvβ3 inhibition and mediated by c-Abl and ASM, which we identified in our current work.

Taken together, we have demonstrated that apoptosis induced by RGDIV is mediated by increase in ASM mRNA and ASM activity through a c-Abl-dependent mechanism (Fig. 6). These data link for the first time the pro-apoptotic function of c-Abl to ASM-dependent apoptosis and establish the molecular ordering of c-Abl in apoptosis induced by inhibition of integrins αvβ3/αvβ5.

Acknowledgments

We thank Dr. Susan Lee (Children’s Hospital Los Angeles) for critical review of the manuscript and helpful discussions and suggestions.

Author Contributions

Conceived and designed the experiments: XR JX JPC MHK AE. Performed the experiments: XR JX JPC MHK. Analyzed the data: XR JX JPC MHK AE. Contributed reagents/materials/analysis tools: XR JX JPC MHK AE. Wrote the paper: XR JX JPC MHK AE.

References

1. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11–25.
2. Desgrosellier JS, Chersh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9–22.
3. Lorger M, Krueger JS, O’Neal M, Staflin K, Felding-Habermann B (2009) Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A 106: 10666–10671.
4. Felding-Habermann B, Mueller BM, Romerdahl CA, Chersh DA (1992) Involvement of integrin αvβ5 gene expression in human melanoma tumorigenicity. J Clin Invest 90: 2018–2022.
5. Bello L, Francolini M, Marthin P, Zhang J, Carroll RS, et al. (2001) αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 49: 380–389; discussion 390.
6. Desgrosellier JS, Barnes LA, Sheld DJ, Huang M, Lau SK, et al. (2009) An alpha(v)beta3 antagonist as a potential target for tumor angiogenesis. J Natl Cancer Inst 101: 890 and CoALL-05–92. Leukemia 10: 957–963.
7. Mahabeleshwar GH, Chen J, Feng W, Somanath PR, Razorenova OV, et al. (2008) Integrin affinity modulation in angiogenesis. Cell Cycle 7: 355–347.
8. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, et al. (1996) C-terminal aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610–5617.
9. Taga T, Suzuki A, Gonzales-Gomez I, Gilles FH, Stins MF, et al. (2002) The avb3 integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98: 690–697.
10. Mathias S, Pena LA, Kolesnick RN (1998) Signal transduction of stress via ceramide. Biochem J 335 (Pt 3): 9764–9769.
11. Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, et al. (2005) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 23: 1651–1657.
12. Kroesen BJ, Pettus B, Labeto C, Busman M, Sietama H, et al. (2003) Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated Clb6-ceramide and involves mitochondria. J Biol Chem 276: 13606–13614.
13. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, et al. (2003) The alpha(v)beta3 integrin antagonist cilengitide inhibits angiogenesis in severe combined immunodeficiency (SCID) mice. Blood 102: 465–480.
14. Schwartz CL, Bruckenstein A, Neeman M, Gao Y, Sina A, et al. (2002) Cilengitide, an arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610–5617.
15. Vonderheide RH, Bosenberg MW, Zou Y, Khurana-Jauhari S, de Bono JS, et al. (2007) Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A 104: 12405–12410.
16. Wang JY (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene 21: 5947–5958.
17. Genersch E, Forletta M, Virtanen I, Haller H, Ekhholm P (2003) Integrin alpha beta 3 binding to human alpha 3-laminin facilitates FGF-2- and VEGF-
induced proliferation of human ECV304 carcinoma cells. Eur J Cell Biol 82: 105–117.

36. Maupas-Schwalm F, Bedel A, Auge N, Grazide MH, Mucher E, et al. (2009) Integrin αvβ3, metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect. Cell Signal 21: 1925–1934.

37. Erdreich-Epstein A, Tran LB, Rosman NN, Wang H, Cahot MC, et al. (2002) Ceramide signaling in feretinindeuced endothelial cell apoptosis. J Biol Chem 277: 49531–49537.

38. Bielawski J, Szulc ZM, Hannun YA, Belawaskya A (2006) Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82–91.

39. Gulbins E, Kolesnick R (2002) Acid sphingomyelinase-derived ceramide signaling in apoptosis. Subcell Biochem 36: 229–244.

40. Reynolds LE, Wyder L, Lively JT, Taverna D, Robinson SD, et al. (2002) Enhanced pathological angiogenesis in mice lacking β3 integrin or β3α and β5 integrins. Nat Med 8: 27–34.

41. Zaidan YH, Hannun YA (2007) Activation of acid sphingomyelinase by protein kinase Cdelta-mediated phosphorylation. The Journal of biological chemistry 282: 11549–11561.

42. Grassme H, Cremesti A, Koelsnick R, Gulbins E (2003) Ceramide-mediated clustering is required for CID95-DISC formation. Oncogene 22: 5457–5470.

43. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, et al. (1995) Regulation of the Fas apoptotic cell death pathway by ABL. J Biol Chem 270: 22625–22631.

44. Barila D, Rufini A, Condo I, Ventura N, Dorey K, et al. (2003) Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol 23: 2790–2797.

45. Zaidan YH, Jenkins RW, Hannun YA (2008) Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol 181: 335–350.

46. Rebillard A, Risso-Lecercq N, Muller C, Bellaud P, Jouan F, et al. (2008) Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage. Oncogene 27: 6590–6595.

47. Goulis S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, et al. (2009) Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15: 1179–1185.

48. Lewis JM, Truong TN, Schwartz MA (2002) Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc Natl Acad Sci U S A 99: 3627–3632.

49. Truong T, Sun G, Doorly M, Wang JY, Schwartz MA (2003) Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci U S A 100: 10291–10296.

50. Gong JG, Costanzo A, Yang HQ, Melino G, Kaedin WG, et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 896–899.

51. Stromblad S, Becker JC, Yehera M, Brooks PG, Cheresh DA (1996) Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426–433.

52. van Bolden A, Varella-Garcia M, Korch G, Miller GJ (2001) TSU-P1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 61: 6340–6344.

53. Koos B, Ihrmann A, Lümenburger H, Mertsch S, Supponen NN, et al. (2010) The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors. Cancer 116: 5073–5081.

54. Woodring P, Litwack ED, O'Leary DD, Lacerre GR, Wang JY, et al. (2002) Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol 156: 879–892.

55. Woodring P, Hunter T, Wang JY (2003) Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 116: 2613–2626.

56. Woodring P, Hunter T, Wang JY (2001) Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J Biol Chem 276: 27104–27110.

57. Rebillard A, Josan-Lanhouet S, Jouan E, Legembre P, Pazon M, et al. (2010) Cisplatin-induced apoptosis involves a Fas-ROCK-erzin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 46: 1445–1455.

58. Bhattacharya S, Fu C, Bhattacharya J, Greenberg S (1995) Soluble ligands of the αvβ3 integrin mediate enhanced tyrosine phosphorylation of multiple proteins in adherent bovine pulmonary artery endothelial cells. J Biol Chem 270: 16781–16787.